Metagenome-Wide Association Study for T2D Biomarker Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on Type 2 Diabetes (T2D) primarily focuses on genetic components, with limited understanding of the role of the intestinal microbiome, and existing methods lack effective biomarkers for early detection and classification.
Innovation Solution
A Metagenome-Wide Association Study (MGWAS) using deep shotgun sequencing of gut microbial DNA from 344 Chinese individuals identified ~60,000 T2D-associated markers, and a disease classifier system was developed based on 50 optimal gene markers using the minimum redundancy-maximum relevance (mRMR) feature selection method, enabling the computation of a gut healthy index for risk evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If genome-wide association studies (GWAS) focusing on genetic components are used, then genetic contributors to T2D can be identified, but the role of the intestinal microbiome remains poorly understood
Solution Approach 1:
The patent applies metagenome-wide association studies (MGWAS) to simultaneously investigate both genetic components and intestinal microbiome factors in T2D research. This multi-functional approach allows the same study framework to capture multiple risk factor types, thereby reducing information loss about T2D etiology while maintaining research scope efficiency.
2Measurement precision
If 16S rRNA and whole-genome shotgun sequencing are used for metagenomic research, then an overall picture of commensal microbial communities can be obtained, but specific T2D-associated biomarkers are insufficient
Solution Approach 1:
The patent extracts and focuses on specific microbial genes and metabolites from the complex metagenomic data that are most strongly associated with T2D. By identifying and isolating these key biomarkers (such as specific bacterial species and metabolic pathways), the method achieves high T2D detection accuracy while reducing the complexity of interpretation compared to analyzing the entire microbiome profile.
Solution Approach 2:
The patent applies local quality by differentiating between various microbial components and their specific functions in T2D pathogenesis. Instead of treating the microbiome as a homogeneous entity, the method identifies specific bacterial taxa, genes, and metabolic pathways that have localized and distinct associations with T2D risk, enabling precise biomarker selection.
3Reliability
If a comprehensive metagenomic analysis is performed, then gut microbial content can be characterized, but effective biomarkers for early detection and classification are lacking
Solution Approach 1:
The patent employs statistical association methods and machine learning algorithms that provide feedback loops for biomarker validation. The MGWAS framework iteratively identifies microbial features associated with T2D, validates these associations, and refines the biomarker panel based on the strength and consistency of associations, thereby improving classification reliability while systematically managing the difficulty of biomarker identification.
Data Source
AI summary
Biomarkers for diabetes and usages thereof are provided. And the biomarkers are nucleotides having polynucleotide sequences defined in SEQ ID NOs: 1-50.